About Katie

Katie Kazem's practice focuses on corporate and securities law and includes the general representation of both public and private companies, with particular experience in advising European life sciences companies on IPOs, capital raising, SEC compliance and corporate governance. She has experience working on M&A, public offerings and venture capital financings.

Representative company-side and underwriter-side public offerings:

  • Valneva SE – $107.6 million IPO, $102.0 million follow-on offering 
  • Nanobiotix SA – $113.3 million IPO
  • Genfit SA - $155.4 million IPO
  • Innate Pharma SA - $79.1 million IPO
  • MaxCyte, Inc. - $201.8 million IPO
  • Renalytix plc - $74.3 million IPO
  • Landos Biopharma – $100 million IPO 
  • 2U – $119.3 million IPO 
  • Aclaris Therapeutics – $105 million follow-on offering 
  • Autolus Therapeutics – $150 million IPO 
  • Biohaven Pharmaceuticals - $193.5 million IPO 
  • Clearside – aggregate $77.4 million IPO and follow-on offering 
  • Entasis Therapeutics – $75 million IPO 
  • Erytech – $125 million IPO
Download full bio

Education

  • George Mason University, Antonin Scalia Law School
    JD, magna cum laude, 2010
  • George Mason University, School of Public Policy
    MA, 2007
  • College of William & Mary
    BA, Government, Monroe Scholar, 2003